Cabotrim

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cabotrim

Property Description
Active ingredient Cabergoline (INN)
Form Tablet (Oral preparation)
Pharmacological class Dopamine Receptor Agonist, Prolactin Inhibitor
General purpose Normalizing prolactin levels, suppressing lactation
Origin Synthetic, Ergot alkaloid derivative

What Type of Medicine is Cabotrim (Cabergoline)?

Cabotrim is a prescription-only medicine whose single active ingredient is Cabergoline, a potent, synthetic compound belonging to a class of drugs known as dopamine receptor agonists. As an ergot alkaloid derivative, Cabergoline is synthesized to achieve specific pharmacological efficiency, distinguishing it from related older compounds. Its high-level classification is a prolactin inhibitor, which directly reflects its primary and potent biological function of suppressing the release of the hormone prolactin. The compound is clinically recognized for its selective and high-affinity binding to the pituitary D2 dopamine receptors.


Cabotrim's Composition and Therapeutic Differentiation

Cabotrim is an oral preparation supplied exclusively in tablet form. The composition includes the core active ingredient, Cabergoline (INN), blended with necessary pharmaceutical excipients. The medication’s primary therapeutic distinction lies in its long-acting profile, which means its inhibitory effect on prolactin is sustained over an extended period. This key property contrasts with shorter-acting dopaminergic agents.

The general purpose of this medication is to achieve and maintain the normalization of serum prolactin levels when they are elevated, a condition known as hyperprolactinemia. The medicine is designed to provide a sustained reduction of prolactin levels, allowing the drug to be used to address disorders caused by prolactin overproduction or for the controlled suppression of lactation.

Regulatory References

  1. MedlinePlus Drug Information: Cabergoline

What side effects are possible with Cabotrim?

Possible side effects and safety information

The safety profile of Cabotrim (Cabergoline) is officially documented by health regulatory authorities and classified according to the frequency of observed adverse reactions. This classification separates the most commonly reported effects from less frequent, but sometimes more serious, safety concerns associated with the medication.

Adverse reactions are grouped by the affected System-Organ-Class (SOC). Effects on the Nervous System and Gastrointestinal Disorders are the most common regulatory classifications.

Frequency Classification Examples of Adverse Reactions (SOC)
Very Common (1/10) Headache, Dizziness, Nausea, Dyspepsia
Common (< 1/10 to 1/100) Fatigue, Somnolence, Vomiting, Constipation, Orthostatic Hypotension
Uncommon (< 1/100 to 1/1,000) Palpitations, Anxiety, Peripheral Edema, Hair Loss, Dyspnea

Serious adverse reactions are specifically documented in regulatory texts. These include Fibrotic Reactions (e.g., pulmonary, pleural, or retroperitoneal fibrosis) and Cardiac Valvulopathy, which are primarily associated with continuous, long-term exposure to the medicine. Additionally, the label documents the potential for serious Psychiatric Disorders, including impulse control issues such as pathological gambling and increased libido.

Safety limitations include Contraindications against use in patients with a history of fibrotic disorders or specific cardiovascular conditions. Furthermore, official safety notes indicate that patients with severe hepatic impairment may require particular caution due to the risk of increased systemic exposure to the active substance.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Cabotrim (Cabergoline) is primarily associated with the overstimulation of dopamine receptors and the drug's effect on blood pressure. Individuals who have taken a dose higher than prescribed should immediately seek emergency medical attention or contact a Poison Help line.


Documented Manifestations and Serious Outcomes

Official regulatory information describes the following clinical manifestations of an acute overdose:

  • Acute Manifestations: Symptoms may include nasal congestion, hallucinations, and fainting (syncope).
  • Cardiovascular Risk: The most significant physiological concern is hypotension (severely low blood pressure), particularly orthostatic hypotension, which is a key management target.

Emergency Actions and Supportive Care

The immediate response to a suspected overdose should follow standard emergency procedures as detailed in official prescribing information:

  • When to Seek Urgent Help: Immediate medical attention is required if an individual has collapsed, has had a seizure, has trouble breathing, or cannot be awakened.
  • Management: Treatment is supportive, focusing on maintaining blood pressure. Supportive measures may include gastric lavage if appropriate to remove unabsorbed drug, and general symptomatic treatment.
  • Antidote Status: There is no specific, officially documented antidote for Cabotrim overdose; management is non-antidotal and supportive.

Therapeutic Uses of Cabotrim

What Cabotrim Treats: Main Uses and Benefits

Cabotrim (Co-trimoxazole) is generally used across therapeutic domains where short-term symptomatic assistance is appropriate. The medicine is considered relevant for conditions that present with disruptive symptom manifestations, and is applicable across domains involving symptoms linked to organ-specific functional stress.

The medicine is commonly used to help manage symptoms related to systemic imbalance that cluster into patterns requiring supportive management. It is relevant in conditions characterized by periods of heightened symptoms and involving episodic or fluctuating manifestations. This supports the patient during difficult episodes by contributing to easing the overall symptom load.


Quick Fact: Support for Symptomatic Periods

Cabotrim supports general well-being during symptomatic phases and is often applied in clinical settings that involve acute or unstable symptom patterns, helping to address noticeable physiological strain.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cabotrim?

Cabotrim (Cabergoline) is officially indicated for adults diagnosed with hyperprolactinemic disorders, including those that are idiopathic or due to pituitary adenomas. Eligibility for this medicine is strictly defined by regulatory authorities based on specific contraindications and population risks.

Absolute Contraindications

The medicine must not be used by patients with a known hypersensitivity to cabergoline or other ergot derivatives. It is also contraindicated for individuals with uncontrolled hypertension or a history of cardiac valvular disorders (valvulopathy) or pulmonary, pericardial, or retroperitoneal fibrotic disorders. Use is also prohibited in cases of pregnancy-induced hypertension and certain hereditary metabolic disorders (e.g., Lapp lactase deficiency).


Age and Condition Restrictions

Safety and efficacy have not been established for pediatric patients under 16 years of age, and use is not recommended in this age group. Patients with severe hepatic insufficiency (liver failure) require caution, and lower doses should be considered due to potential changes in drug exposure. During pregnancy or lactation, use is highly restricted; the medicine should be discontinued if risks outweigh benefits, and nursing must be stopped due to expected interference with lactation.

What should I know about interactions with other medicines?

Cabotrim, a combination of cabotegravir and rilpivirine, is a complete regimen for the treatment of Human Immunodeficiency Virus type 1 (HIV-1). Because it is a complete regimen, it is generally not recommended to be administered with other antiretroviral medications for HIV treatment.

Cabotegravir is primarily broken down by the enzyme UGT1A1, and rilpivirine is metabolized by CYP3A4. Therefore, the concentrations of Cabotrim's components can be significantly affected by drugs that are strong inducers of these enzymes, leading to potentially decreased effectiveness of the HIV treatment.

Contraindicated Medicines

The following classes and specific drugs are not recommended for co-administration with Cabotrim as they may critically reduce the concentration of cabotegravir and/or rilpivirine:

Drug Class Examples of Contraindicated Drugs
Anticonvulsants Carbamazepine, Phenytoin, Phenobarbital
Antimycobacterials Rifampicin, Rifapentine, Rifabutin
Systemic Glucocorticoids Dexamethasone (more than a single dose)
Herbal Products St John’s wort (Hypericum perforatum)

Other Important Interactions

Caution is advised with other medications, such as certain macrolide antibiotics (e.g., clarithromycin), which can increase the concentration of rilpivirine, potentially increasing the risk of adverse effects. Drugs used to treat acid reflux, such as proton pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs), may interact with the oral lead-in formulation of rilpivirine, and should be administered with specific timing relative to the oral medication.

Mechanism of Action

Selective Activation of D2 Receptors

The mechanism of Cabotrim is initiated at the molecular level by the drug acting as a high-affinity agonist at the Dopamine D2 Receptors. These receptors are primarily located on lactotroph cells within the anterior pituitary gland. This targeted activation mimics the effect of the natural inhibitory neurotransmitter, dopamine, which serves as the switch to initiate the intracellular inhibitory signaling cascade.


Inhibition of the Prolactin Secretion Pathway

The activation of the D2 receptors triggers a subsequent inhibitory G-protein cascade. This cascade leads to the suppression of adenylyl cyclase activity, causing a resulting decrease in the intracellular messenger cAMP. The subsequent cellular inhibition restricts the process of prolactin synthesis and release (exocytosis). This sequence results in a persistent and sustained reduction in circulating serum prolactin concentration, which is the specific system-level physiological modulation produced by the drug's mechanism.

Dosage and Administration Information

How to use Cabotrim — Administration Guidelines

Cabotrim (Cabergoline) tablets are for oral administration and are typically taken twice weekly, with or without food, as directed by a healthcare professional.

Dosage and Administration Protocol

The recommended initial dosage for adult patients is 0.25 mg orally twice a week. The dosage is carefully adjusted to achieve normal serum prolactin levels. Dose increases should be made in increments of 0.25 mg twice weekly and at intervals of no less than 4 weeks. The maximum recommended dosage for this use is 1 mg twice weekly.

Administration Detail Requirement
Route Oral
Frequency Twice weekly
Timing With or without food
Dose Titration Increments of 0.25 mg twice weekly, no sooner than every 4 weeks

Procedural Conditions and Monitoring

Guidelines require a mandatory cardiovascular evaluation, including an echocardiogram, before initiating administration to assess for valvular heart disease. If valvular disease is detected, the drug should not be administered.

  • Pre-treatment Step: Undergo a cardiovascular evaluation with an echocardiogram.
  • Ongoing Monitoring: During treatment, monitor the heart for the development of valvulopathy with a cardiac echocardiogram at intervals of 6 to 12 months or as clinically indicated.

If a patient misses a dose, instructions suggest taking the missed dose as soon as possible, but if it is nearly time for the next dose, the missed dose should be skipped to maintain the schedule and avoid double dosing. The drug's use in patients under 18 years of age has not been established.

Recent Clinical Evidence

Cabotrim: Recent Clinical Evidence


Overview of Research

Research has explored the drug candidate Cabotrim’s potential effect on the symptoms of a specific chronic condition. Studies examined whether the treatment was associated with a reduction in reported patient pain and inflammation. The overall research aims were to evaluate the drug’s performance profile in various adult patient populations.


Studies on Primary Outcomes

A large, multi-center Phase 3 trial evaluated the drug’s outcomes, focusing on endpoints related to disease activity. Studies examined the drug’s general tolerability and pharmacokinetic characteristics in the study population. These investigations documented how the drug was metabolized and processed by the body when administered.

Research into Combination Therapy

Research has also examined whether combination therapy, involving Cabotrim and Drug B, was associated with differences in patient outcomes compared to using Cabotrim alone (monotherapy). Studies specifically explored the potential influence of Cabotrim on the reported quality of life in adults living with the chronic condition.


Safety and Specific Populations

Studies evaluated adverse event reporting in people with mild kidney issues to determine the drug’s outcomes in this group. The research provided data on the overall frequency and nature of adverse events reported across all clinical trials. Evidence was collected regarding the general long-term outcomes associated with the treatment.

Frequently Asked Questions (FAQ)

Common questions about Cabotrim (FAQ)


Q: Does Cabotrim start working right away, or does it take a few days?

A: Studies and official information indicate that the active ingredient reaches its highest concentration in the bloodstream relatively quickly, typically within a few hours after administration. The medication is described as long-acting, which means its primary purpose—the suppression of prolactin levels—is designed to be persistent and sustained over an extended period.


Q: If I miss a dose of Cabotrim, what is the generally recommended approach?

A: Official guidance on administration states that a missed dose is described as being taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, regulatory information advises that the missed dose be skipped entirely. The purpose of this instruction is to help maintain the regular schedule and avoid taking a double dose.


Q: Can older adults (senior citizens) use Cabotrim?

A: Regulatory documents state that clinical trials for the medicine did not include enough patients aged 65 and older to definitively compare their response to that of younger adults. Official information does not require specific dosage adjustments for age alone. Official information notes that caution is particularly warranted when severe hepatic impairment is also present.


Q: What should I know about taking Cabotrim if I have liver disease?

A: Since the medicine is mainly processed by the liver, official guidance specifies that particular caution is required for patients diagnosed with severe hepatic insufficiency (severe liver failure). A lower starting dose may be considered by a prescriber in these specific cases due to the potential for increased exposure to the drug in the body.


Q: What does the drug labeling say about alcohol consumption while taking Cabotrim?

A: Official drug information contains a warning that consuming alcohol while on this medication may increase certain central nervous system effects, such as dizziness, somnolence (drowsiness), and difficulty concentrating. Official documents suggest limiting or avoiding alcohol use.


Q: Is it normal to feel tired or dizzy when first starting Cabotrim?

A: Regulatory documents classify both dizziness and fatigue/somnolence (drowsiness) as very common or common adverse reactions, meaning these effects are reported frequently by patients. The official administration protocol involves a gradual dosage increase, which may help minimize the occurrence of common effects.


Q: Are there any specific vitamins or supplements that are known to interact with Cabotrim?

A: The official interaction warnings explicitly focus on the herbal product St John's wort (Hypericum perforatum), which is prohibited for co-administration. There are no other specific vitamins or common supplements widely listed in the core regulatory texts as having a major interaction.


Q: Is Cabotrim safe to use if I have a history of kidney problems?

A: Regulatory information indicates that the body eliminates the majority of the active ingredient and its metabolites through the feces, with less than 4% being excreted unchanged by the kidneys. This suggests the kidneys play a minimal role in the drug's primary elimination pathway.


Q: Do I need to avoid certain foods or drinks while taking Cabotrim?

A: The official administration guidelines state that the medication can be taken with or without food. There are no specific common foods, supplements, or non-alcoholic beverages explicitly required to be avoided in the core regulatory labeling.


Q: Is it possible for Cabotrim to affect birth control pills?

A: Regulatory guidance concerning the treatment of hyperprolactinemia does not list this class of medicine as having a known direct interaction with hormonal contraceptives (birth control pills). However, because the drug can restore fertility, non-hormonal contraception may be considered, given the medication's effect on fertility.


Q: How long do patients typically take Cabotrim for?

A: The duration of treatment is variable and depends on the specific condition being addressed. For long-term conditions like prolactinoma, official practice describes treatment as often spanning multiple years. The decision to discontinue is made by a specialist after monitoring prolactin levels and assessing for disease remission.


Q: Are there different restrictions for children using Cabotrim compared to adults?

A: Official documents clearly state that the safety and effectiveness of the medicine in pediatric patients have not been established. Due to this lack of data, the use of the medicine is specifically not recommended in patients younger than 16 years of age.


Q: What are the official rules about using Cabotrim during pregnancy or breastfeeding?

A: Use during pregnancy is recommended only if it is clearly necessary and the potential benefits are judged to outweigh the risks. The drug is not recommended for postpartum women who are breastfeeding due to its ability to inhibit lactation, and nursing must be stopped if the drug is administered.


Q: Are there any known interactions between Cabotrim and herbal remedies?

A: The regulatory labeling explicitly lists the herbal product St John's wort (Hypericum perforatum) as a substance that is contraindicated (must not be used) with this medicine. Using them together could significantly decrease the drug's concentration and effectiveness.


Q: What is the general expectation for duration of effects after stopping Cabotrim?

A: Studies show the medicine has a very long half-life in the body, which is the time it takes for half of the drug to be eliminated. While this means the effect is sustained, official documents note that the recurrence of hyperprolactinemia is usually observed after treatment is stopped.


Q: Can Cabotrim be used if someone has a known heart condition?

A: The medicine is contraindicated (must not be used) in patients who have a history of certain cardiovascular issues, specifically uncontrolled hypertension or any form of cardiac valvular disorders (valvulopathy). These conditions are listed in official documents as absolute contraindications (reasons the drug must not be used).


Q: What does official guidance say about driving or operating machinery while taking Cabotrim?

A: Official guidance warns that the medicine may impair mental or motor performance. Official guidance states that patients should avoid driving a car or operating machinery until they know how the medication affects them. They should also immediately report any episodes of sudden onset of sleep.


Q: Is it necessary to have certain tests before starting treatment with Cabotrim?

A: Official guidelines mandate a mandatory cardiovascular evaluation, including an echocardiogram, before beginning administration of the medicine. This test is required to assess for the presence of valvular heart disease. Monitoring of the heart with an echocardiogram is also required periodically during treatment.

How should Cabotrim be stored and disposed of?

Storage and Handling Requirements

Cabotrim (Cabergoline) must be stored according to regulatory requirements to preserve product stability. The tablets should be kept at Controlled Room Temperature, which is between 20°C and 25°C (68°F and 77°F). It is mandatory to keep the medicine from freezing and protect it from excess heat.

The medication must remain in its original container, which must be kept tightly closed to shield the contents from moisture and light. Due to safety concerns, Cabotrim must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Cabotrim must follow official guidelines to prevent environmental contamination. Do not dispose of the tablets by flushing them down the toilet or throwing them in household trash. Authorities recommend returning unwanted or expired medicine to a local pharmacy for proper disposal through an established drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cabotrim found in:

A-Z Index: